We are live on
!
Find out more
First Trust Advisors Portfolio holdings
AUM
$140B
1-Year Est. Return
27.84%
This Fund
S&P 500
This Quarter
Est. Return
+1.3%
1 Year Est. Return
+27.84%
3 Year Est. Return
+78.79%
5 Year Est. Return
+98.89%
10 Year Est. Return
+456.9%
AUM
$38.5B
AUM Growth
+$4.48B
(+13%)
Cap. Flow
+$4.55B
Cap. Flow
% of AUM
11.82%
Top 10 Holdings %
Top 10 Hldgs %
13.89%
Holding
2,364
New
149
Increased
1,180
Reduced
895
Closed
134
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
First Trust NYSE Arca Biotechnology Index Fund
FBT
|
+$275M |
| 2 |
First Trust Health Care AlphaDEX Fund
FXH
|
+$221M |
| 3 |
First Trust Dow Jones Internet Index Fund ETF
FDN
|
+$193M |
| 4 |
First Trust Consumer Staples AlphaDEX Fund
FXG
|
+$188M |
| 5 |
First Trust Consumer Discretionary AlphaDEX Fund
FXD
|
+$179M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
PCYC
PHARMACYCLICS INC
PCYC
|
+$230M |
| 2 |
Spectrum Brands
SPB
|
+$81.6M |
| 3 |
Chevron
CVX
|
+$79.8M |
| 4 |
Pfizer
PFE
|
+$66.7M |
| 5 |
K
Kellanova
K
|
+$63.3M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 22.09% |
| 2 | Consumer Discretionary | 10.38% |
| 3 | Technology | 9.81% |
| 4 | Consumer Staples | 7.93% |
| 5 | Communication Services | 6.56% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
76
Celldex Therapeutics
CLDX
$2.76B
| $110M | 0.28% |
289,492
-26,304
| -8% | -$10.4M |
|
77
Hain Celestial
HAIN
$49.5M
| $109M | 0.28% |
1,655,939
-322,175
| -16% | -$20.3M |
|
78
Ingredion
INGR
$6.38B
| $107M | 0.28% |
1,335,618
+252,474
| +23% | +$20.3M |
|
|
TWTR
79
DELISTED
Twitter, Inc.
TWTR
| $105M | 0.27% |
2,903,308
+847,293
| +41% | +$34.6M |
|
|
GRFS
80
Grifois
GRFS
$5.17B
| $105M | 0.27% |
6,787,854
+1,090,234
| +19% | +$17.7M |
|
81
Universal Health Services
UHS
$9.69B
| $104M | 0.27% |
731,259
+106,723
| +17% | +$13.4M |
|
82
Merck
MRK
$324B
| $103M | 0.27% |
1,894,480
+1,769,824
| +1,420% | +$99.3M |
|
83
Ionis Pharmaceuticals
IONS
$9.38B
| $102M | 0.27% |
1,779,289
+393,695
| +28% | +$25M |
|
84
Microsoft
MSFT
$2.86T
| $100M | 0.26% |
2,269,699
-53,587
| -2% | -$2.45M |
|
85
TripAdvisor
TRIP
$1.6B
| $98.5M | 0.26% |
1,130,513
+254,971
| +29% | +$20.7M |
|
|
CERN
86
DELISTED
Cerner Corp
CERN
| $98.1M | 0.25% |
1,420,224
+427,797
| +43% | +$29.9M |
|
87
Intel
INTC
$489B
| $92.7M | 0.24% |
3,046,310
-1,476,267
| -33% | -$47.7M |
|
|
HOLX
88
DELISTED
Hologic
HOLX
| $91.3M | 0.24% |
2,398,370
+1,853,493
| +340% | +$64.9M |
|
89
Viatris
VTRS
$20.2B
| $89.6M | 0.23% |
1,320,963
-46,567
| -3% | -$3.29M |
|
90
Verizon
VZ
$189B
| $88.4M | 0.23% |
1,896,543
-535,186
| -22% | -$26.2M |
|
91
IBM
IBM
$202B
| $87.9M | 0.23% |
565,127
-29,082
| -5% | -$4.67M |
|
|
RAI
92
DELISTED
Reynolds American Inc
RAI
| $87.8M | 0.23% |
2,350,754
+1,074,464
| +84% | +$40.2M |
|
93
Edwards Lifesciences
EW
$49.3B
| $86.9M | 0.23% |
3,662,670
-396,654
| -10% | -$8.95M |
|
94
Zoetis
ZTS
$31.6B
| $86.7M | 0.22% |
1,797,086
+331,072
| +23% | +$15.8M |
|
95
Boston Scientific
BSX
$66.3B
| $84.7M | 0.22% |
4,782,963
+3,683,141
| +335% | +$65.8M |
|
96
AbbVie
ABBV
$458B
| $84.3M | 0.22% |
1,254,434
-227,104
| -15% | -$14.8M |
|
|
WFM
97
DELISTED
Whole Foods Market Inc
WFM
| $83.4M | 0.22% |
2,115,509
+220,635
| +12% | +$9.87M |
|
|
JNPR
98
DELISTED
Juniper Networks
JNPR
| $83.1M | 0.22% |
3,199,517
-1,072,798
| -25% | -$28.2M |
|
99
Henry Schein
HSIC
$9.78B
| $81.4M | 0.21% |
1,461,221
-160,135
| -10% | -$8.86M |
|
100
Pediatrix Medical
MD
$2.17B
| $80.6M | 0.21% |
1,088,219
+126,560
| +13% | +$9.11M |
|
Similar funds
DAM
First Trust Advisors's Q2 2015 Portfolio in Review
As of Q2 2015, First Trust Advisors held 2,364 positions worth $38.5B, up 13% from $34B the previous quarter. Its ten largest holdings account for 14% of the portfolio.
First Trust Advisors deployed $4.55B of net new capital in Q2 2015, opening 149 new positions and adding to 1,180 existing holdings. Its largest new stake was Agios Pharmaceuticals: 1,079,286 shares worth $120M.
By sector, the portfolio is most concentrated in Healthcare at 22% of assets, up from 21% a quarter earlier, followed by Consumer Discretionary and Technology.
On the sell side, the largest reduction was Chevron, an estimated $79.8M trimmed.
- First Trust Advisors's largest Q2 2015 buy was Agios Pharmaceuticals: 1,079,286 shares worth $120M.
- First Trust Advisors added most to First Trust NYSE Arca Biotechnology Index Fund in Q2 2015, an estimated $275M increase.
- First Trust Advisors's biggest Q2 2015 reduction was Chevron, cutting an estimated $79.8M.
- First Trust Advisors fully exited PHARMACYCLICS INC in Q2 2015, selling an estimated $230M.
- First Trust Advisors's ten largest holdings make up 14% of its $38.5B portfolio in Q2 2015.
- First Trust Advisors opened 149 new positions and closed 134 in Q2 2015.
- First Trust Advisors's portfolio value rose 13% quarter-over-quarter to $38.5B.
Based on First Trust Advisors's 13F filing for Q2 2015, filed 4 Aug 2015.